Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
Completed
377 enrolled
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Phase 1/2 Completed
215 enrolled 30 charts
MiGHT
Phase NA Completed
831 enrolled
CATALYST
Phase NA Completed
50 enrolled
PREPARE
Phase NA Completed
792 enrolled
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
Phase 1 Completed
21 enrolled
Sequential EHR Based Interventions to Increase Genetic Testing for Breast and Ovarian Cancer Predisposition
Phase NA Completed
1,330 enrolled
Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk
Completed
40 enrolled
Endoxifen in Adults With Hormone Receptor Positive Solid Tumors
Phase 1 Completed
40 enrolled
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903
Phase 1 Completed
69 enrolled
A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors
Phase 2 Completed
25 enrolled 11 charts
BRIDGEScohort2
Phase NA Completed
405 enrolled
INOVOLINE
Phase NA Completed
101 enrolled
LEAP-005
Phase 2 Completed
611 enrolled 27 charts
Study of ESG401 in Adults With Solid Tumors
Phase 1/2 Completed
156 enrolled
EARN
Phase NA Completed
33 enrolled
GLIMMER-01
Phase 1/2 Completed
69 enrolled 13 charts
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Phase 1/2 Completed
145 enrolled 47 charts
OLAP
Completed
661 enrolled
KEYVIBE-005
Phase 2 Completed
613 enrolled
CNSI-Fe(II)
Phase 1 Completed
19 enrolled 47 charts
Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies
Phase 1 Completed
23 enrolled
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
Phase 1 Completed
54 enrolled
PRIORITY
Completed
346 enrolled 9 charts
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
Phase 1 Completed
285 enrolled
EXODIAG
Phase NA Completed
71 enrolled
Doxil/Caelyx BE Study
Phase 1 Completed
36 enrolled
P-COC
Phase NA Completed
60 enrolled
GRACE
Phase NA Completed
668 enrolled 25 charts
Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer Survivors
Phase NA Completed
40 enrolled
Improved Early Diagnosis in Female Pelvic Cancer With OC Detect
Completed
490 enrolled
PREFER
Completed
1,429 enrolled
A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
Phase 1 Completed
112 enrolled
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Phase NA Completed
128 enrolled 24 charts
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
Phase 1 Completed
26 enrolled
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
Phase 1 Completed
121 enrolled
Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations
Phase 1 Completed
10 enrolled
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Phase 1/2 Completed
169 enrolled
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Phase 1 Completed
12 enrolled
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Phase 1 Completed
279 enrolled
Study of Continuous OSI-906 Dosing
Phase 1 Completed
95 enrolled
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Phase 1/2 Completed
26 enrolled 14 charts
IVY
Phase 1 Completed
353 enrolled
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
Phase 1 Completed
29 enrolled
A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors
Phase 1 Completed
190 enrolled
A Crossover Bioequivalence Study of Olaparib Tablets, 150 mg (Lek Pharmaceuticals d.d.) and Lynparza® (Olaparib) Tablets 150 mg (AstraZeneca Pharmaceuticals LP), in Patients With Breast Cancer Gene (BRCA) Mutated Ovarian Cancer, Recurrent Ovarian Cancer or Metastatic Breast Cancer
Phase 1 Completed
70 enrolled 13 charts
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
Phase 1 Completed
73 enrolled 18 charts
PrevTel
Phase 2 Completed
35 enrolled
Vaccine Therapy and Cyclophosphamide in Treating Patients With Stage II-III Breast or Stage II-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase 1 Completed
24 enrolled
Evaluation of the Safety and Tolerability of Niraparib With Everolimus in Advanced Gynecologic Malignancies and Breast
Phase 1 Completed
14 enrolled 12 charts